Zoono share price: where next as Coronavirus crisis intensifies

We examine some of Zoono's key fundamentals as well as a number of the company's operational ambitions for FY20.

‘One is left wondering if this kind of price action is sustainable.’

That was one of the key points we made last week after the Zoono share price made new highs: It surged to $2.29 per share on 5 March, before giving up most of those gains in the following days.

The antimicrobial stock currently trades around the $1.44 mark, more than 40% off those highs, mind you. (Though the stock is still up ~1,600% over the last 12-months.)

Manias after all work both ways: yet they tend to be more pronounced on the way down, a notion well illustrated by the price action of equities from the last few days.

The ASX 200 collapsed 7.3% on Monday, then plunged another 3% in the first 30 minutes of trade today, though the market has rebounded a shade since then. The blue-chip benchmark is currently hovering around the 5,700 point mark, its lowest point since January 2019.

Across the globe there are now 114,299 cases of the Coronavirus (COVID-19) and 4,025 reported deaths.

Where do you stand: is this the start of larger share price declines or do you think Zoono will rebound? Trade accordingly. To go short (sell) or long (buy) on Zoono, using IG's world class trading platform, follow these simple steps:

  • Set up an IG Trading Account or log in to your existing account
  • Enter ‘Zoono’ or ‘ZNO’ in the search bar and select it
  • Choose your position size
  • Click on ‘buy’ or ‘sell’ in the deal ticket
  • Confirm the trade

Zoono share price: fundamentals in focus

Looking at Zoono’s most recent half-yearly results – released in late February – we see a distinct improvement in fundamentals.

All up, the company not only posted stronger top-line growth, but it tightened its losses during the half. H1 revenue more than doubled, surging 144% to NZ$1,714,980; while losses sharply decreased, dropping 47% to NZ$727,944.

In saying that, at a market capitalisation of over $200 million – Zoono (ASX: ZNO) currently trades on a lofty sales multiple – by historical standards.

Looking at where Zoono aims to head next, and speaking of the company’s ‘evolving business’ model, as part of the H1 it was noted that:

'The major focus of the Company in the current [FY20] financial year is the further evolution of its business model, particularly in regard to adding to its network of distributors in key countries and/or regions and building on-line sales.'

Zoono's management finished by saying:

'The ultimate objective is to increase repeat sales at better margins from longer term direct contracts with larger multinational customers.'

As an aside, it’s important to note that any uptick in sales related to the Coronavirus crisis were not factored into Zoono’s H1 results, which covered the half period ending 31 December 2019.

Finally, and in regard to our initial point: the market looks to have decisively voted that Zoono’s exponential share price action was unsustainable: ZNO dropped ~20% at the open today, plunging as low as $1.31 per share within the first 30 minutes of trade.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.